Compugen (Compugen) Short-Term Debt : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Compugen Short-Term Debt?

Compugen's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.

Compugen Short-Term Debt Historical Data

The historical data trend for Compugen's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen Short-Term Debt Chart

Compugen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

Compugen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Compugen Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Compugen Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Compugen's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Compugen (Compugen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (NAS:CGEN) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

CGEN:Israel

Address

26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849

Website

https://www.cgen.com

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.